title: Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
abstract: When diagnosed at an early stage, resection of pancreatic neuroendocrine tumors (NETs) is often curative. Unfortunately, curative surgery is rarely an option for patients with metastatic disease. Multiple options are available for the management of patients with advanced pancreatic NETs, including surgery, liver-directed therapy, and systemic therapies. Because of the heterogeneity of disease biology and presentation, a multidisciplinary approach to management is critical. Treatment with somatostatin analogs, sunitinib, everolimus, and alkylating agents provide effective systemic therapeutic options for patients. Future studies to evaluate the optimal timing, sequence, and combination of therapies, as well as to identify predictors of response, are warranted.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1220, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: jang@partners.org.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Chan
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1220, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Kulke
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
keywords: Everolimus; Pancreatic neuroendocrine tumor; Somatostatin analogue; Sunitinib; Temozolomide; mTOR